Medicare's AI Experiment: A Cautionary Tale of Speed Over Safety

Medicare's AI Experiment: A Cautionary Tale of Speed Over Safety

When the Centers for Medicare & Medicaid Services (CMS) launched the WISeR program in January, it was hailed as a bold step toward modernizing healthcare administration. The initiative aimed to use artificial intelligence to review prior authorization requests for certain medical procedures—a process that can be time-consuming and administrative. But what started as an ambitious effort to improve efficiency has instead become a cautionary tale about the perils of deploying untested technology in high-stakes healthcare environments.

"The problem isn't just the algorithm. Medicare inserted AI into prior authorization before parts of the technology and the surrounding process were fully tested and working together," said Michael Ryan, a finance expert and founder of MichaelRyanMoney.com. "The result is a faster way to create a bottleneck."

The WISeR program is currently operating in six states: Texas, Arizona, New Jersey, Ohio, Oklahoma, and Washington. It covers 13 medical services deemed vulnerable to fraud, waste, or inappropriate use. The idea was simple: private contractors would manage the AI-powered tech platforms, which would assist with evaluating requests before treatment.

What Went Wrong?

Newly released documents from a Freedom of Information Act (FOIA) lawsuit brought by the Electronic Frontier Foundation (EFF) paint a stark picture. The records reveal significant operational issues since the program's launch, including:

• Unprecedented delays: Despite CMS stating that vendors should respond within 72 hours, one request went unanswered for an alarming 83 days.
• System outages and technical failures: Providers reported frequent disruptions in the tech platforms, causing confusion and additional burden on already stretched medical staff.
• Inappropriate denials: There were instances of denials that were not only medically unjustified but also potentially harmful to patient care.
• Patient harm: Reports suggest delays in necessary treatment due to prolonged approval times.

Kevin Thompson, CEO of 9i Capital Group and host of the 9innings podcast, echoed these concerns: "If you show me the incentive, I'll show you the outcome, and that is what you are seeing here: increased denials and longer prior authorization timelines."

The EFF's investigation raises serious questions about how thoroughly AI systems were tested before being deployed. CMS's own FAQ page acknowledges that the model is under review, but critics argue that this response lacks urgency.

Previous Warnings Ignored

These issues are not new. Previous reports from KFF Health News in June highlighted similar concerns among doctors and patients participating in the pilot program. Medical professionals described the rollout as "horrendous," while medical organizations said physicians were forced to rapidly adapt to new administrative requirements.

"The biggest concern is delayed treatment. Longer approval times mean patients may not get the care they need when they need it," Thompson noted.

The program's rapid expansion, despite mounting evidence of operational failures, suggests a troubling pattern: pushing technology before establishing its safety and reliability.

The Hidden Risk of AI in Healthcare

One of the most alarming aspects of the WISeR program is the role AI plays in influencing human decisions—even when clinicians are formally responsible for final authorization. EFF's documents suggest that AI-generated recommendations often shape human reviewers' judgments, creating a potential for bias and error.

This situation underscores a broader issue in the use of AI in healthcare: the lack of transparency and oversight. Without rigorous safeguards, AI systems can lead to unwarranted delays or denials of necessary medical care, particularly affecting vulnerable populations like seniors.

"In the absence of rigorous safeguards, AI-driven prior authorization determinations can lead to unwarranted—and even discriminatory—delays or denials of necessary medical care," EFF stated in a recent statement.

Furthermore, there is little public knowledge about the actual AI systems being used by WISeR vendors. This opacity makes it difficult for providers and patients to understand how decisions are made, which undermines trust and accountability in Medicare's new model.

A Systematic Problem

It's not just about technical glitches—it's about a fundamental misalignment between CMS's priorities and the real-world needs of patients. The WISeR program, intended to cut costs and increase efficiency, has instead created a bureaucratic bottleneck that may be costing lives.

Michael Ryan, who has closely followed healthcare policy, believes the CMS will continue to expand this model regardless of its shortcomings. "WISeR is scheduled through 2031, and CMS clearly sees technology-assisted prior authorization as part of the future," he said. "But expanding it before proving it can consistently make care faster and safer would be getting the order backward."

For those in the healthcare industry, the WISeR experiment is a stark reminder that technological innovation must never come at the cost of patient safety. AI has tremendous potential to improve health outcomes—but only if it's deployed thoughtfully, with appropriate testing, transparency, and oversight.

What's Next?

The EFF lawsuit continues to push for greater transparency and accountability from CMS regarding its use of AI in Medicare programs. Until these issues are addressed, we must ask: What is more important—efficiency or care? And who gets to decide that?

As the debate continues, one thing remains clear: any future AI implementation in healthcare must be grounded in rigorous testing, real-world feedback, and a commitment to patient-centered outcomes. The stakes are simply too high to rush anything less.